Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meridia's CV Risks Not Distinguishable By Subgroups, FDA Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Eight of 16 members of Endocrinologic and Metabolic Drugs Advisory Committee vote to take Abbott's obesity drug off the market, saying no subgroup can be identified in which the cardiovascular risks could be managed through a Risk Evaluation and Mitigation Strategy.
Advertisement

Related Content

REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance
FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance
Can CV Monitoring Warnings Or REMS Restrictions Save Abbott's Meridia?
Can CV Monitoring Warnings Or REMS Restrictions Save Abbott's Meridia?

Topics

Advertisement
UsernamePublicRestriction

Register

PS071177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel